» Articles » PMID: 30322191

Functional and Endoscopic Indicators for Percutaneous Endoscopic Gastrostomy (PEG) in Amyotrophic Lateral Sclerosis Patients

Overview
Journal J Clin Med
Specialty General Medicine
Date 2018 Oct 17
PMID 30322191
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative condition, whose bulbar involvement compromises language, swallowing, and airway protection. When oral nutrition is no longer adequate, percutaneous endoscopic gastroscopy (PEG) may be indicated. However, as exact timing is still debatable, we tried to find it. (2) Methods: A prospective cohort study was performed using fiber-optic endoscopic evaluation of swallowing (FEES), functional evaluation scales (ALS Functional Rating Scale-Revised (ALSFRS-R) and bulbar sub-score (ALSFRS-R-B)), lung function tests (like Forced Vital Capacity (FVC), Cough Peak Flow (CPF)) and anthropometric data. (3) Results: Twenty-three patients were enrolled (mean 65.4 ± 9.1 years, 60.9% males), 12 with spinal-onset. During the study period, 58 FEES were performed (1⁻4/patients). Even before formal the PEG indication, suggestions were given to correct the alterations found. PEG was placed in 12 patients, on average 21.8 months after diagnosis (FVC = 69.9% ± 26.7%, ALSFRS-R-B = 7.7 ± 3.7, ALSFRS-R = 28.9 ± 12.3), and being 91.7% under ventilatory support. ALSFRS-R-B, CPF, FVC, and ALSFRS-R showed significant discriminant ability for PEG placement. Sensitivity and specificity were, respectively, ALSFRS-R-B ≤ 8 (100/90.9), CPF ≤ 205 (83.3), FVC ≤ 74 (83.3/74.2), and ALSFRS-R < 29 (83.3/65.1). (4) Conclusions: FEES provide additional information beyond formal PEG indication. ALSFRS-R-B score ≤ 8 was found as a best functional and noninvasive indicator for PEG performance in ALS patients.

Citing Articles

Dysphagia Assessments as Criteria in the 'Decision-Making Process' for Percutaneous Endoscopic Gastrostomy Placement in People with Amyotrophic Lateral Sclerosis: A Systematic Review.

Kotsia E, Chroni E, Alexandropoulou A, Mills C, Veltsista D, Kefalopoulou Z Dysphagia. 2024; 39(6):977-988.

PMID: 38517530 PMC: 11606986. DOI: 10.1007/s00455-024-10686-2.


Sonographic and 3T-MRI-based evaluation of the tongue in ALS.

Hensiek N, Schreiber F, Wimmer T, Kaufmann J, Machts J, Fahlbusch L Neuroimage Clin. 2020; 26:102233.

PMID: 32171167 PMC: 7068685. DOI: 10.1016/j.nicl.2020.102233.

References
1.
Burgos R, Breton I, Cereda E, Desport J, Dziewas R, Genton L . ESPEN guideline clinical nutrition in neurology. Clin Nutr. 2017; 37(1):354-396. DOI: 10.1016/j.clnu.2017.09.003. View

2.
Aviv J, Kaplan S, Thomson J, Spitzer J, Diamond B, Close L . The safety of flexible endoscopic evaluation of swallowing with sensory testing (FEESST): an analysis of 500 consecutive evaluations. Dysphagia. 1999; 15(1):39-44. DOI: 10.1007/s004559910008. View

3.
Thompson A, Blackwell V, Marsden R, Millard E, Lawson C, Nickol A . A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18(3-4):243-248. PMC: 5425625. DOI: 10.1080/21678421.2016.1274330. View

4.
Onesti E, Schettino I, Gori M, Frasca V, Ceccanti M, Cambieri C . Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. Front Neurol. 2017; 8:94. PMC: 5359548. DOI: 10.3389/fneur.2017.00094. View

5.
Tabor L, Gaziano J, Watts S, Robison R, Plowman E . Defining Swallowing-Related Quality of Life Profiles in Individuals with Amyotrophic Lateral Sclerosis. Dysphagia. 2016; 31(3):376-82. PMC: 4871719. DOI: 10.1007/s00455-015-9686-2. View